Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835Open textbooks209Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation›References

Continue where you left off ()

Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 18 min read

  1. Abdel-Fattah M, Chapple C, Guerrero K, Dixon S, Cotterill N, Ward K, et al. Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study): a superiority randomised clinical trial to evaluate the effectiveness and cost-effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms. Trials 2021;22:745.34702331
  2. Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al.; International Urogynecological Association. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn 2010;29:4–20.19941278
  3. National Institute for Health and Care Excellence. Urinary Incontinence and Pelvic Organ Prolapse in Women: Management. Clinical Guideline [NG123] . 2019. URL: www.nice.org.uk/guidance/ng123 (accessed 20 May 2020).
  4. Abrams P, Cardozo LD, Fall M, Griffiths DJ, Rosier P, Ulmsten U, et al.; Standardisation Sub-committee of the International Continence Society. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.11857671
  5. Hampel C, Wienhold D, Benken N, Eggersmann C, Thuroff JW. Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997;50:4–14; discussion 15.9426746
  6. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S; Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trøndelag. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT Study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 2000;53:1150–7.11106889
  7. Perry S, Shaw C, Assassa P, Dallosso H, Williams K, Brittain KR, et al. An epidemiological study to establish the prevalence of urinary symptoms and felt need in the community: the Leicestershire MRC Incontinence Study. Leicestershire MRC Incontinence Study Team. J Public Health Med 2000;22:427–34.11077920
  8. Milsom I, Coyne KS, Nicholson S, Kvasz M, Chen C, Wein AJ. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur Urol 2014;65:79–95.24007713
  9. Komesu YM, Schrader RM, Ketai LH, Rogers RG, Dunivan GC. Epidemiology of mixed, stress, and urgency urinary incontinence in middle-aged/older women: the importance of incontinence history. Int Urogynecol J 2016;27:763–72.26670573
  10. Irwin DE, Kopp ZS, Agatep B, Milsom I, Abrams P. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011;108:1132–8.21231991
  11. Ebbesen MH, Hunskaar S, Rortveit G, Hannestad YS. Prevalence, incidence and remission of urinary incontinence in women: longitudinal data from the Norwegian HUNT study (EPINCONT). BMC Urol 2013;13:27.23721491
  12. Wennberg A, Molander U, Fall M, Edlund C, Peeker R, Milsom I. A longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol 2009;55:783–91.19157689
  13. Wang C, Wan X, Wang K, Li J, Sun T, Guan X. Disease stigma and intentions to seek care for stress urinary incontinence among community-dwelling women. Maturitas 2014;77:351–5.24602555
  14. Hung KJ, Awtrey CS, Tsai AC. Urinary incontinence, depression, and economic outcomes in a cohort of women between the ages of 54 and 65 years. Obstet Gynecol 2014;123:822–7.24785611
  15. Kwak Y, Kwon H, Kim Y. Health-related quality of life and mental health in older women with urinary incontinence. Aging Ment Health 2016;20:719–26.25876190
  16. Nygaard I, Turvey C, Burns TL, Crischilles E, Wallace R. Urinary incontinence and depression in middle-aged United States women. Obstet Gynecol 2003;101:149–56.12517660
  17. Langa KM, Fultz NH, Saint S, Kabeto MU, Herzog AR. Informal caregiving time and costs for urinary incontinence in older individuals in the United States. J Am Geriatr Soc 2002;50:733–7.11982676
  18. Norton PA, MacDonald LD, Sedgwick PM, Stanton SL. Distress and delay associated with urinary incontinence, frequency, and urgency in women. BMJ 1988;297:1187–9.3144344
  19. Turner DA, Shaw C, McGrother CW, Dallosso HM, Cooper NJ; MRC Incontinence Team. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK. BJU Int 2004;93:1246–52.15180616
  20. Fultz NH, Burgio K, Diokno AC, Kinchen KS, Obenchain R, Bump RC. Burden of stress urinary incontinence for community-dwelling women. Am J Obstet Gynecol 2003;189:1275–82.14634553
  21. Subak LL, Brubaker L, Chai TC, Creasman JM, Diokno AC, Goode PS, et al.; Urinary Incontinence Treatment Network. High costs of urinary incontinence among women electing surgery to treat stress incontinence. Obstet Gynecol 2008;111:899–907.18378749
  22. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology 2003;62:28–37; discussion 40.14662404
  23. Steers WD. Pathophysiology of overactive bladder and urge urinary incontinence. Rev Urol 2002;4:S7–18.16986023
  24. Andersson K, Pehrson R. CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention. Drugs 2003;63:2595–611.14636079
  25. National Institute for Health and Care Excellence. Urinary Incontinence in Women: Management. Clinical Guideline [CG171] . 2013. URL: www.nice.org.uk/guidance/cg171 (accessed 21 February 2017).
  26. Abrams P, Avery K, Gardener N, Donovan J; ICIQ Advisory Board. The international consultation on incontinence modular questionnaire: www.iciq.net. J Urol 2006;175:1063–6; discussion 1066.16469618
  27. Shumaker SA, Wyman JF, Uebersax JS, McClish D, Fanti JA. Health-related quality of life measures for women with urinary incontinence: the incontinence impact questionnaire and the urogenital distress inventory. Qual Life Res 1994;3:291–306.7841963
  28. Uebersax JS, Wyman JF, Shumaker SA, McClish DK, Fantl JA. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 1995;14:131–9.7780440
  29. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A new questionnaire to assess the quality of life of urinary incontinent women. Br J Obstet Gynaecol 1997;104:1374–9.9422015
  30. Rogers RG, Coates KW, Kammerer-Doak D, Khalsa S, Qualls C. A short form of the pelvic organ prolapse/urinary incontinence sexual questionnaire (PISQ-12). Int Urogynecol J Pelvic Floor Dysfunct 2003;14:164–8; discussion 168.12955337
  31. Rogers RG, Rockwood TH, Constantine ML, Thakar R, Kammerer-Doak DN, Pauls RN, et al. A new measure of sexual function in women with pelvic floor disorders (PFD): the pelvic organ prolapse/incontinence sexual questionnaire, IUGA-revised (PISQ-IR). Int Urogynecol J 2013;24:1091–103.23632798
  32. Abrams P, Cardozo L, Wagg A, Wein A. Epidemiology of Urinary Incontinence (UI) and Other Lower Urinary Tract Symptoms (LUTS), Pelvic Organ Prolapse (POP) and Anal Incontinence (AI). Incontinence. 6th edn. 2016. URL: www.ics.org/publications/ici_6/Incontinence_6th_Edition_2017_eBook_v2.pdf (accessed 20 December 2023).
  33. Ku JH, Jeong IG, Lim DJ, Byun S, Paick J, Oh S. Voiding diary for the evaluation of urinary incontinence and lower urinary tract symptoms: prospective assessment of patient compliance and burden. Neurourol Urodyn 2004;23:331–5.15227650
  34. Nygaard I, Holcomb R. Reproducibility of the seven-day voiding diary in women with stress urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2000;11:15–7.10738929
  35. Bodmer NS, Wirth C, Birkhauser V, Sartori AM, Leitner L, Averbeck MA, et al. Randomised controlled trials assessing the clinical value of urodynamic studies: a systematic review and meta-analysis. Eur Urol Open Sci 2022;44:131–41.36110903
  36. Romero MJ, Ortiz GMA, Gomez PL, Lopez LA, Sanchez A, Pacheco BJJ. Does pressure flow study improve the outcome of surgery in women with SUI? Eur Urol Suppl 2010;9:228.
  37. Nager CW, Brubaker L, Litman HJ, Zyczynski HM, Varner RE, Amundsen C, et al.; Urinary Incontinence Treatment Network. A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med 2012;366:1987–97.22551104
  38. van Leijsen SA, Kluivers KB, Mol BW, Broekhuis SR, Milani AL, Bongers MY, et al. Can preoperative urodynamic investigation be omitted in women with stress urinary incontinence? A non-inferiority randomized controlled trial. Neurourol Urodyn 2012;31:1118–23.22488817
  39. Osman NI, Li Marzi V, Cornu JN, Drake MJ. Evaluation and classification of stress urinary incontinence: current concepts and future directions. Eur Urol Focus 2016;2:238–44.28723369
  40. Pessoa R, Kim FJ. Urodynamics and Voiding Dysfunction. In Harken AH, Moore EE, editors. Abernathy’s Surgical Secrets. Amsterdam: Elsevier; 2018. pp. 452–54.
  41. Hubeaux K, Deffieux X, Jousse M, Amarenco G. Correlation between voiding dysfunction symptoms and uroflowmetry in women suffering from stress urinary incontinence. Indian J Urol 2012;28:313–7.23204661
  42. Deitel M, Stone E, Kassam HA, Wilk EJ, Sutherland DJ. Gynecologic-obstetric changes after loss of massive excess weight following bariatric surgery. J Am Coll Nutr 1988;7:147–53.3361039
  43. Subak LL, Wing R, West DS, Franklin F, Vittinghoff E, Creasman JM, et al.; PRIDE Investigators. Weight loss to treat urinary incontinence in overweight and obese women. N Engl J Med 2009;360:481–90.19179316
  44. Dumoulin C, Cacciari LP, Hay-Smith EJC. Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women. Cochrane Database Syst Rev 2018;10:CD005654.30288727
  45. Aksac B, Aki S, Karan A, Yalcin O, Isikoglu M, Eskiyurt N. Biofeedback and pelvic floor exercises for the rehabilitation of urinary stress incontinence. Gynecol Obstet Invest 2003;56:23–7.12867764
  46. Hagen S, Elders A, Stratton S, Sergenson N, Bugge C, Dean S, et al. Effectiveness of pelvic floor muscle training with and without electromyographic biofeedback for urinary incontinence in women: multicentre randomised controlled trial. BMJ 2020;371:m3719.33055247
  47. Zia A, Kamaruzzaman S, Myint PK, Tan MP. Anticholinergic burden is associated with recurrent and injurious falls in older individuals. Maturitas 2016;84:32–7.26531071
  48. Wein AJ. Diagnosis and treatment of the overactive bladder. Urology 2003;62:20–7.
  49. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al.; Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217–22.18499184
  50. Rovner E, Kennelly M, Schulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn 2011;30:556–62.21351127
  51. Chapple C, Sievert K, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol 2013;64:249–56.23608668
  52. Rachaneni S, McCooty S, Middleton LJ, Parker VL, Daniels JP, Coomarasamy A, et al.; Bladder Ultrasound Study (BUS) Collaborative Group. Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Health Technol Assess 2016;20:1–150.
  53. Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, van Kerrebroeck PE. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999;162:352–7.10411037
  54. Siegel SW, Catanzaro F, Dijkema HE, Elhilali MM, Fowler CJ, Gajewski JB, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000;56:87–91.
  55. Hassouna MM, Siegel SW, Nyeholt AA, Elhilali MM, van Kerrebroeck PE, Das AK, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol 2000;163:1849–54.10799197
  56. Groenendijk PM, Lycklama à Nyeholt AA, Heesakkers JP, van Kerrebroeck PE, Hassouna MM, Gajewski JB, et al.; Sacral Nerve Stimulation Study Group. Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence. BJU Int 2008;101:325–9.18070199
  57. Mohee A, Khan A, Harris N, Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int 2013;111:106–13.22672569
  58. Marcelissen TA, Rahnama’i MS, Snijkers A, Schurch B, De Vries P. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms. World J Urol 2017;35:307–11.27272312
  59. Leong RK, de Wachter SG, Joore MA, van Kerrebroeck PE. Cost-effectiveness analysis of sacral neuromodulation and botulinum toxin A treatment for patients with idiopathic overactive bladder. BJU Int 2011;108:558–64.21166750
  60. Digesu GA, Hutchings A, Salvatore S, Selvaggi L, Khullar V. Reproducibility and reliability of pressure flow parameters in women. BJOG 2003;110:774–6.12892691
  61. Coyne KS, Sexton CC, Thompson CL, Milsom I, Irwin D, Kopp ZS, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352–60.19281467
  62. Shaw C, Williams K, Assassa PR, Jackson C. Patient satisfaction with urodynamics: a qualitative study. J Adv Nurs 2000;32:1356–63.11136403
  63. Ku JH, Kim SW, Kim HH, Paick JS, Son H, Oh SJ. Patient experience with a urodynamic study: a prospective study in 208 patients. J Urol 2004;171:2307–10.15126810
  64. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z, Herschorn S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306–14; discussion 1314.17049716
  65. Digesu GA, Salvatore S, Fernando R, Khullar V. Mixed urinary symptoms: what are the urodynamic findings? Neurourol Urodyn 2008;27:372–5.17943988
  66. Mobley DF, Baum N. Etiology, evaluation, and management of nocturia in elderly men and women. Postgrad Med 2014;126:147–53.24685979
  67. Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S. Treatment with solifenacin increases warning time and improves symptoms of overactive bladder: results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 2009;73:14–8.18995887
  68. Ramsay IN, Ali HM, Hunter M, Stark D, Donaldson K. A randomized controlled trial of urodynamic investigations prior to conservative treatment of urinary incontinence in the female. Int Urogynecol J Pelvic Floor Dysfunct 1995;6:277–81.
  69. Rosier PFWM, Schaefer W, Lose G, Goldman HB, Guralnick M, Eustice S, et al. International Continence Society good urodynamic practices and terms 2016: urodynamics, uroflowmetry, cystometry, and pressure-flow study. Neurourol Urodyn 2017;36:1243–60.27917521
  70. Denys P, Le Normand L, Ghout I, Costa P, Chartier-Kastler E, Grise P, et al.; VESITOX Study Group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur Urol 2012;61:520–9.22036776
  71. Sealed Envelope Ltd. Power Calculator for Binary Outcome Superiority Trial. 2012. URL: www.sealedenvelope.com/power/binary-superiority/ (accessed 22 September 2012).
  72. Wittes J. Sample size calculations for randomized controlled trials. Epidemiol Rev 2002;24:39–53.12119854
  73. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.
  74. McNamara S, Schneider PP, Love-Koh J, Doran T, Gutacker N. Quality-adjusted life expectancy norms for the English population. Value Health 2023;26:163–9.35965226
  75. National Institute for Health and Care Excellence. NICE Health Technology Evaluations: The Manual. 2023. URL: www.nice.org.uk/process/pmg36/chapter/introduction-to-health-technology-evaluation (accessed 6 June 2023).
  76. National Institute for Health and Clinical Excellence. Position Statement on Use of the EQ-5D-5L Value Set for England. 2019. URL: www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/technology-appraisal-guidance/eq-5d-5l (accessed 18 June 2020).
  77. Hernandez-Alava M, Pudney S. Eq5Dmap: a command for mapping between EQ-5D-3L and EQ-5D-5L. Stata J 2018;18:395–415.
  78. Ramsey SD, Willke RJ, Glick H, Reed SD, Augustovski F, Jonsson B, et al. Cost-effectiveness analysis alongside clinical trials II: an ISPOR good research practices task force report. Value Health 2015;18:161–72.25773551
  79. Manca A, Hawkins N, Sculpher MJ. Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility. Health Econ 2005;14:487–96.15497198
  80. Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. PharmacoEconomics 2014;32:1157–70.25069632
  81. Glick H, Doshi J, Sonnad S, Polsky D. Economic Evaluation in Clinical Trials. 1st edn. New York: Oxford University Press; 2007.
  82. Sculpher M. Clinical trials provide essential evidence, but rarely offer a vehicle for cost-effectiveness analysis. Value Health 2015;18:141–2.25773547
  83. Philips Z, Claxton K, Palmer S. The half-life of truth: what are appropriate time horizons for research decisions? Med Decis Making 2008;28:287–99.18448701
  84. Desroziers K, Aballea S, Maman K, Nazir J, Odeyemi I, Hakimi Z. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder. Health Qual Life Outcomes 2013;11:200.24246044
  85. Versteegh MM, Leunis A, Uyl-de Groot CA, Stolk EA. Condition-specific preference-based measures: benefit or burden? Value Health 2012;15:504–13.22583461
  86. Duperrouzel C, Martin C, Mendell A, Bourque M, Carrera A, Mack A, Nesheim J. Healthcare and economic burden of anticholinergic use in adults with overactive bladder: a systematic literature review. J Comp Eff Res 2022;11:1375–94.36354285
  87. Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six western countries. BJU Int 2009;103:202–9.19278532
  88. Al-Busaidi ZQ. Qualitative research and its uses in health care. Sultan Qaboos Univ Med J 2008;8:11–9.21654952
  89. O’Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Hewison J. What can qualitative research do for randomised controlled trials? A systematic mapping review. BMJ Open 2013;3:e002889
  90. Fusch PI, Ness L. Are we there yet? Data saturation in qualitative research. Qual Rep 2015;20:1408–16.
  91. Adeoye-Olatunde OA, Olenik NL. Research and scholarly methods: semi-structured interviews. J Am Coll Clin Pharm 2021;4:1358–67.
  92. Maguire M, Delahunt B. Doing a thematic analysis: a practical, step-by-step guide for learning and teaching scholars. All Ireland J High Educ 2017;9:3351–4.
  93. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101.
  94. Nowell LS, Norris JM, White DE, Moules NJ. Thematic analysis: striving to meet the trustworthiness criteria. Int J Qual Methods 2017;16:1–13.
  95. National Institute for Health and Care Excellence. Urinary Incontinence and Pelvic Organ Prolapse in Women: Management. URL: www.nice.org.uk/guidance/ng123 (accessed 5 June 2023).
  96. Brown S, Wyman J. Women’s experiences with urodynamic testing for urinary incontinence: a systematic review. Female Pelvic Med Reconstruct Surg 2015;21:85–91.
  97. Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M. Women’s experiences of two types of urodynamic investigation: a randomized controlled trial. Obstet Gynecol 2009;114:687–94.
  98. Wyman, JF, Fantl, JA. Urodynamics. In Partin AW, Peters CA, Kavoussi LR, Dmochowski RR, Wein AJ, editors. Campbell-Walsh Urology. Vol. 1. 11th edn. Amsterdam: Elsevier; 2014. pp. 628–52.
  99. Gammie A, Almeida F, Drake M, Finazzi Agrò E, Kirschner-Hermanns R, Lemos N, et al. Is the value of urodynamics undermined by poor technique?: ICI-RS 2018. Neurourol Urodyn 2019;38:S35–9.31821637
  100. Aiello M, Jelski J, Lewis A, Worthington J, McDonald C, Abrams P, et al. Quality control of uroflowmetry and urodynamic data from two large multicenter studies of male lower urinary tract symptoms. Neurourol Urodyn 2020;39:1170–7.32187720
  101. Gammie A, Clarkson B, Constantinou C, Damaser M, Drinnan M, Geleijnse G, et al.; International Continence Society Urodynamic Equipment Working Group. International Continence Society guidelines on urodynamic equipment performance. Neurourol Urodyn 2014;33:370–9.24390971
  102. Tincello DG, Kenyon S, Abrams KR, Mayne C, Toozs-Hobson P, Taylor D, Slack M. Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study). Eur Urol 2012;62:507–14.22236796
  103. Corcos J, Beaulieu S, Donovan J, Naughton M, Gotoh M; Symptom Quality of Life Assessment Committee of the First International Consultation on Incontinence. Quality of life assessment in men and women with urinary incontinence. J Urol 2002;168:896–905.12187188
  104. Karantanis E, Fynes M, Moore KH, Stanton SL. Comparison of the ICIQ-SF and 24-hour pad test with other measures for evaluating the severity of urodynamic stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct 2004;15:111–6; discussion 116.15014938
  105. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003;189:98–101.12861145
  106. Abdel-Fattah M, Cooper D, Davidson T, Kilonzo M, Hossain M, Boyers D, et al. Single-incision mini-slings for stress urinary incontinence in women. N Engl J Med 2022;386:1230–43.35353961
  107. Serati M, Braga A, Athanasiou S, Tommaselli GA, Caccia G, Torella M, et al. Tension-free vaginal tape-obturator for treatment of pure urodynamic stress urinary incontinence: efficacy and adverse effects at 10-year follow-up. Eur Urol 2017;71:674–9.27597239
  108. Ulrich D, Tammaa A, Holbfer S, Trutnovsky G, Bjelic-Radisic V, Tamussino K, Aigmüller T. Ten-year followup after tension-free vaginal tape-obturator procedure for stress urinary incontinence. J Urol 2016;196:1201–6.27181504
  109. Larsen MD, Lose G, Guldberg R, Gradel KO. Discrepancies between patient-reported outcome measures when assessing urinary incontinence or pelvic-prolapse surgery. Int Urogynecol J 2016;27:537–43.26407560
  110. Cartwright R, Brown H, Rizk D. Patient reported outcome measures after incontinence and prolapse surgery: are the pictures painted by the ICIQ and PGI-I accurate? Int Urogynecol J 2016;27:507–8.26755053
  111. Sirls LT, Tennstedt S, Brubaker L, Kim HY, Nygaard I, Rahn DD, et al. The minimum important difference for the international consultation on incontinence questionnaire – urinary incontinence short form in women with stress urinary incontinence. Neurourol Urodyn 2015;34:183–7.24273137
  112. Nystrom E, Sjostrom M, Stenlund H, Samuelsson E. ICIQ symptom and quality of life instruments measure clinically relevant improvements in women with stress urinary incontinence. Neurourol Urodyn 2015;34:747–51.25154378
  113. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al.; EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol 2013;189:2186–93.23246476
  114. Cro S, Morris TP, Kahan BC, Cornelius VR, Carpenter JR. A four-step strategy for handling missing outcome data in randomised trials affected by a pandemic. BMC Med Res Methodol 2020;20:208.32787782
  115. Goranitis I, Barton P, Middleton LJ, Deeks JJ, Daniels JP, Latthe P, et al. Testing and treating women after unsuccessful conservative treatments for overactive bladder or mixed urinary incontinence: a model-based economic evaluation based on the BUS study. PLOS ONE 2016;11:e0160351.27513926
  116. Homer T, Shen J, Vale L, McColl E, Tincello DG, Hilton P; INVESTIGATE-I studies group Invasive urodynamic testing prior to surgical treatment for stress urinary incontinence in women: cost-effectiveness and value of information analyses in the context of a mixed methods feasibility study. Pilot Feasibil Stud 2018;4:67.
  117. Hilton P, Armstrong N, Brennand C, Howel D, Shen J, Bryant A, et al.; INVESTIGATE Studies Group. INVESTIGATE-I (INVasive Evaluation before Surgical Treatment of Incontinence Gives Added Therapeutic Effect?): a mixed-methods study to assess the feasibility of a future randomised controlled trial of invasive urodynamic testing prior to surgery for stress urinary incontinence in women. Health Technol Assess 2015;19:1–273, vii.
  118. Arlandis S, Castro D, Errando C, Fernández E, Jiménez M, González P, et al. Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder. Value Health 2011;14:219–28.21402292
  119. Martinson M, MacDiarmid S, Black E. Cost of neuromodulation therapies for overactive bladder: percutaneous tibial nerve stimulation versus sacral nerve stimulation. J Urol 2013;189:210–6.23174264
  120. Autiero SW, Hallas N, Betts CD, Ockrim JL. The cost-effectiveness of sacral nerve stimulation (SNS) for the treatment of idiopathic medically refractory overactive bladder (wet) in the UK. BJU Int 2015;116:945–54.25407358
  121. Hassouna MM, Sadri H. Economic evaluation of sacral neuromodulation in overactive bladder: a Canadian perspective. Can Urol Assoc J 2015;9:242–7.26316906
  122. Murray B, Hessami SH, Gultyaev D, Lister J, Dmochowski R, Gillard KK, et al. Cost-effectiveness of overactive bladder treatments: from the US payer perspective. J Comp Eff Res 2019;8:61–71.30511584
  123. Brazzelli M, Javanbakht M, Imamura M, Hudson J, Moloney E, Becker F, et al. Surgical treatments for women with stress urinary incontinence: the ESTER systematic review and economic evaluation. Health Technol Assess 2019;23:1–306.
  124. Lor KY, Soupashi M, Abdel-Fattah M, Mostafa A. Does pre-operative urodynamics lead to better outcomes in management of urinary incontinence in women? A linked systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020;244:141–53.31786491
  125. Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, et al. Five-year followup results of a prospective, multicenter study of patients with overactive bladder treated with sacral neuromodulation. J Urol 2018;199:229–36.28709886
  126. Peeters K, Sahai A, De Ridder D, Van Der Aa F. Long-term follow-up of sacral neuromodulation for lower urinary tract dysfunction. BJU Int 2014;113:789–94.24238278
  127. Marcelissen TA, Leong RK, de Bie RA, van Kerrebroeck PE, de Wachter SG. Long-term results of sacral neuromodulation with the tined lead procedure. J Urol 2010;184:1997–2000.20850820
  128. Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al.; Pelvic Floor Disorders Network. Two-year outcomes of sacral neuromodulation versus OnabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol 2018;74:66–73.29482936
  129. Kessler TM, Buchser E, Meyer S, Engeler DS, Al-Khodairy AW, Bersch U, et al. Sacral neuromodulation for refractory lower urinary tract dysfunction: results of a nationwide registry in Switzerland. Eur Urol 2007;51:1357–63.17113216
  130. Kaaki B, Gupta D. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: a retrospective single-institution study. PLOS ONE 2020;15:e0235961.32645082
  131. Ismail S, Chartier-Kastler E, Perrouin-Verbe M, Rose-Dite-Modestine J, Denys P, Phe V. Long-term functional outcomes of S3 sacral neuromodulation for the Treatment of Idiopathic Overactive Bladder. Neuromodulation 2017;20:825–9.28967986
  132. Al-zahrani AA, Elzayat EA, Gajewski JB. Long-term outcome and surgical interventions after sacral neuromodulation implant for lower urinary tract symptoms: 14-year experience at 1 center. J Urol 2011;185:981–6.21247597
  133. Eldred-Evans D, Sahai A. Medium- to long-term outcomes of botulinum toxin A for idiopathic overactive bladder. Ther Adv Urol 2017;9(1):3–10.28042308
  134. Liu P, Li Y, Shi B, Zhang Q, Guo H. Comparison of different types of therapy for overactive bladder: a systematic review and network meta-analysis. Front Med (Lausanne) 2022;9:1014291.36341256
  135. Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, et al.; 191622-096 Investigators. Durable efficacy and safety of long-term OnabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol 2016; 196:791–800.27038769
  136. Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012;61:834–9.22204745
← DiscussionAdditional information →

Attribution. Mohamed Abdel-Fattah; Christopher Chapple; Suzanne Breeman; David Cooper; Helen Bell-Gorrod; Preksha Kuppanda et al. (2025). Invasive urodynamic investigations in the management of women with refractory overactive bladder symptoms: FUTURE, a superiority RCT and economic evaluation. National Institute for Health and Care Research. Copyright © 2025 Abdel-Fattah et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK615958. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support